Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233356 | 0.93 | GNRHR (0.35) | GNRHRCYP2C9CACNA1FCHRM4ADORA3 | |
| SCHEMBL4236673 | 0.92 | GNRHR (0.34) | GNRHRCYP2C9CACNA1FCHRM4ADORA3 | |
| SCHEMBL4237708 | 0.90 | GNRHR (0.33) | GNRHRCYP2C9CACNA1FCHRM4ADORA3 | |
| SCHEMBL4233244 | 0.90 | GNRHR (0.34) | GNRHRIRAK4CYP2C9CACNA1FCHRM4 | |
| SCHEMBL4232018 | 0.87 | IRAK4 (0.43) | GNRHRIRAK4CYP2C9CACNA1FCHRM4 | |
| SCHEMBL4231647 | 0.84 | CACNA1F (0.43) | GNRHRCYP2C9CACNA1FCHRM4ADORA3 | |
| SCHEMBL4227267 | 0.82 | MAPT (0.34) | GNRHRIRAK4CYP2C9MAPTKDM4E | |
| SCHEMBL4621743 | 0.81 | IRAK4 (0.37) | GNRHRIRAK4CYP2C9CACNA1FCHRM4 | |
| SCHEMBL4233369 | 0.80 | GNRHR (0.36) | GNRHRCYP2C9CACNA1FCHRM4ADORA3 | |
| SCHEMBL13743435 | 0.80 | GNRHR (0.35) | GNRHRCYP2C9CACNA1FCHRM4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1896465-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | Takeda Cambridge Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | GNRHR 1/4885IRAK4 4616/4885CYP2C9 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.